<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford E Kashtan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alport syndrome (previously referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities [<a href="#rid1">1</a>].</p><p>The pathogenesis, genetics, and pathology of Alport syndrome will be reviewed here. The clinical manifestations and course, diagnosis, and treatment of Alport syndrome are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">GENETICS</span></p><p class="headingAnchor" id="H1005333823"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Alport syndrome is a primary basement membrane disorder arising from pathogenic variants in genes encoding several members of the collagen IV protein family [<a href="#rid1">1</a>].</p><p>Collagen IV molecules are composed of three alpha chains that form triple-helical structures through specific interactions of C-terminal noncollagenous domains [<a href="#rid2">2</a>]. Six distinct type IV collagen chains are encoded by six different genes that are distributed in head-to-head pairs  (<a class="graphic graphic_figure graphicRef130689" href="/z/d/graphic/130689.html" rel="external">figure 1</a>) on three chromosomes.</p><p>The genes include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120130&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TEFHDbvHnci38F8ZXcX6Z8&amp;TOPIC_ID=6086" target="_blank"><i>COL4A1</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120090&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1QNGJ532C3x5wEsJjdz8o06&amp;TOPIC_ID=6086" target="_blank"><i>COL4A2</i></a> at 13q34</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a> at 2q35-37</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303631&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6Gb%2Bjs8Vg3v5ghAGYrmyIpe&amp;TOPIC_ID=6086" target="_blank"><i>COL4A6</i></a> on chromosome X</p><p></p><p>The six alpha chains of collagen IV form three triple helical protomers: alpha-1-1-2, alpha-3-4-5, and alpha-5-5-6. These protomers are further organized into networks by end-to-end connections via C-terminal and N-terminal interactions.</p><p>Genetic analyses of affected families have identified the affected genes for the four different modes of transmission seen in patients with Alport syndrome, which are discussed in the following sections [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>X-linked</p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal recessive</p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal dominant</p><p class="bulletIndent1"><span class="glyph">●</span>Digenic</p><p></p><p>Pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> genes disrupt the synthesis and/or the formation of collagen IV alpha-3-4-5 protomers and networks. Based on pedigree studies, linkage analysis, and Sanger sequencing, the relative frequencies of the four genetic types were estimated at 80 percent for X-linked disease, 15 percent for autosomal recessive disease, less than 5 percent for autosomal dominant disease, and case reports for digenic inheritance. However, studies using next-generation sequencing in Alport families suggest that autosomal dominant Alport syndrome may occur more frequently (20 to 30 percent of patients) than previously thought [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">X-linked inheritance</span><span class="headingEndMark"> — </span>X-linked Alport syndrome accounts for of the majority of Alport syndrome cases. It arises from pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> gene on the X chromosome, which codes for the alpha-5(IV) chain of collagen IV [<a href="#rid5">5-12</a>].</p><p>Confirmation of the direct pathogenetic role of these mutations was provided by an animal model in which a specific known human nonsense mutation was introduced into the mouse <em>COL4A5</em> gene [<a href="#rid13">13</a>]. The primary clinical and pathologic findings of human X-linked disease were recapitulated in this animal model.</p><p>This mode of inheritance leads to important clinical characteristics in affected families:</p><p class="bulletIndent1"><span class="glyph">●</span>Father-to-son transmission does not occur, since the father passes only the unaffected Y chromosome to the son.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females with X-linked Alport syndrome are heterozygous for disease-causing <em>COL4A5</em> variants. Almost all heterozygotes have some degree of hematuria, and a significant minority develop kidney failure [<a href="#rid14">14</a>]. The variable course in females is probably due to lyonization, by which only one X chromosome is active per cell. As a result, in most females with X-linked Alport syndrome, roughly one-half of the cells will express the variant <em>COL4A5</em> allele and the remaining cells the normal <em>COL4A5</em> allele, leading to a variable phenotype that is generally less severe than in affected males. The influence of X-inactivation on kidney outcomes in heterozygotes has been confirmed in the X-linked Alport syndrome mouse model [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Phenotype-genotype correlation'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Autosomal recessive inheritance</span><span class="headingEndMark"> — </span>Autosomal recessive inheritance accounts for approximately 10 to 15 percent of patients with Alport syndrome [<a href="#rid10">10</a>]. It arises from genetic defects in either the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a> genes. The <em>COL4A3</em> and <em>COL4A4</em> genes encode the alpha-3(IV) chain (which contains the Goodpasture antigen) and the alpha-4(IV) chain, respectively.</p><p>Females are as severely affected as males [<a href="#rid7">7,16,17</a>], and the clinical manifestations in both sexes are virtually identical to those of classic X-linked Alport syndrome in males [<a href="#rid14">14,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Clinical manifestations and course'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Autosomal dominant inheritance</span><span class="headingEndMark"> — </span>Studies utilizing next-generation sequencing have reported approximately 20 to 30 percent of patients with Alport syndrome have autosomal dominant disease, which arises from heterozygous variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a> genes [<a href="#rid3">3,4,18-20</a>]. The clinical features of autosomal dominant genotype are variable, ranging from isolated microscopic hematuria to some individuals who progress to end-stage kidney disease. In a large case series of 82 families with 252 patients, pathogenic variants were identified for both the <em>COL4A3</em> (107 patients from 35 families) and <em>COL4A4</em> (133 patients from 43 families) genes [<a href="#rid21">21</a>]. In this cohort, microhematuria was the most common manifestations (92 percent), followed by proteinuria (65 percent), and extrarenal findings (eg, sensorineural hearing loss and ocular abnormalities) were rare. Approximately one-third of the cohort (n = 61) had progressive disease requiring kidney replacement therapy, all of whom had proteinuria.</p><p>It is unclear why some patients with heterozygous variants in the <em>COL4A3</em> or <em>COL4A4</em> genes exhibit progressive kidney disease (ie, autosomal dominant Alport syndrome), while others have nonprogressive or very slowly progressive kidney disease (historically called "thin basement membrane nephropathy," although some consider this condition to be a form of Alport syndrome) [<a href="#rid1">1,19,20,22</a>]. Some evidence suggests that genetic factors other than mutations in these genes may affect underlying clinical features [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3038.html" rel="external">"Thin basement membrane nephropathy (benign familial hematuria)"</a>.)</p><p class="headingAnchor" id="H4290293290"><span class="h2">Digenic inheritance</span><span class="headingEndMark"> — </span>Rarely, patients with coexisting mutations in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> with digenic inheritance have been reported [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H7"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Elucidation of the pathogenesis of Alport syndrome was facilitated by the chance observation that the glomerular basement membrane (GBM) of most affected patients did not bind antibodies from patients with anti-GBM antibody disease (including Goodpasture syndrome) [<a href="#rid2">2,24-26</a>]. This finding suggested an abnormality in collagen IV, the protein target of anti-GBM antibodies. The alpha-3, alpha-4, and alpha-5(IV) chains are highly expressed and co-distributed within the normal GBM [<a href="#rid27">27</a>]. They form a collagen IV network within the GBM that is distinct from that formed by alpha-1(IV) and alpha-2(IV) chains  (<a class="graphic graphic_figure graphicRef130689" href="/z/d/graphic/130689.html" rel="external">figure 1</a>) [<a href="#rid5">5,28</a>]. Pathogenic genetic variants affecting the alpha-3, alpha-4, and alpha-5(IV) chains impair their deposition into this collagen network, leading to secondary changes in GBM and resident glomerular cells that predispose to the development of glomerulosclerosis. Abnormal expression of collagen IV alpha-3-4-5 networks in basement membranes of the eye and cochlea result in specific ocular anomalies and sensorineural hearing loss.</p><p>Monoclonal antibody probes have been used to determine the tissue distribution of the alpha-3, alpha-4, and alpha-5(IV) chains in normal tissues and tissues from Alport patients.</p><p class="bulletIndent1"><span class="glyph">●</span>Collagen IV chains are normally located in Bowman capsule and the basement membranes of the glomerulus, distal and collecting tubules, and basement membranes of the cochlea and eye [<a href="#rid29">29,30</a>]. Thus, an abnormality in any of these chains can impair the integrity of basement membranes in these sites, leading to the various clinical findings of Alport syndrome. In most patients with alpha-5(IV) variants, the alpha-3, alpha-4 chains, and alpha-5(IV) chains are all absent from the GBM [<a href="#rid12">12,31</a>]. However, transcription of the alpha-3(IV) and alpha-4(IV) genes is not turned off in the kidney cortex, suggesting that failure of incorporation of these chains is responsible for the lack of glomerular expression and not failure of synthesis [<a href="#rid32">32</a>]. (See <a class="local">'Kidney'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In normal individuals, the alpha-5(IV) chain is present in the basement membrane underlying the epidermis as a component of alpha-5-5-6 networks. In individuals with variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> gene on the X chromosome (ie, X-linked inheritance), there is complete absence of alpha-5(IV) chain within epidermal basement membranes in most affected males. (See <a class="local">'Skin'</a> below.)</p><p></p><p class="headingAnchor" id="H2839952485"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H10"><span class="h2">Kidney</span></p><p class="headingAnchor" id="H40485197"><span class="h3">Immunostaining</span><span class="headingEndMark"> — </span>Immunostaining of kidney biopsy specimens for collagen IV can be diagnostic for patients with suspected Alport syndrome  (<a class="graphic graphic_figure graphicRef81373" href="/z/d/graphic/81373.html" rel="external">figure 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked disease</strong> – Males with X-linked Alport syndrome typically show complete absence of immunostaining for the alpha-3, alpha-4, and alpha-5(IV) chains in their kidneys, while heterozygous females exhibit patchy loss of staining in GBM and tubular basement membranes. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1">As with skin staining for the alpha-5(IV) chain, approximately 20 percent of males with X-linked Alport syndrome have normal staining of kidney basement membranes for the alpha-3, alpha-4, and alpha-5(IV) chains. Further quantitative analysis reveals lower amounts of the alpha-3, alpha-4, and/or alpha-5(IV) chains in these cases compared with healthy controls [<a href="#rid33">33</a>]. Some of these patients have missense variants of <em>COL4A5</em>, which may explain the detection of alpha IV chains with immunostaining, albeit with decreased intensity [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive disease</strong> – Individuals with autosomal recessive Alport syndrome have abnormalities of collagen IV expression that differ from those of patients with X-linked disease. These patients typically exhibit complete absence of staining for the alpha-3 and alpha-4(IV) chains. However, while their glomerular basement membranes (GBMs) show no staining for the alpha-5(IV) chain, there is staining of Bowman capsules and distal tubular basement membranes for the alpha-5(IV) chain. This observation can be interpreted as failure of the alpha-5(IV) chain to be deposited in the GBM due to the absence of the alpha-3 and alpha-4(IV) chains, but the alpha-5(IV) chain, in conjunction with the alpha-6(IV) chain, is deposited in the basement membranes of the distal tubule, Bowman capsules, and epidermis.</p><p></p><p class="headingAnchor" id="H374284124"><span class="h3">Histologic changes</span><span class="headingEndMark"> — </span>The changes on light microscopy are nonspecific and include focal increases in glomerular cellularity, progressing to glomerulosclerosis and interstitial fibrosis-tubular atrophy over time, and an interstitial infiltrate containing lipid-laden foam cells. Histologic changes in Alport syndrome typically increase in severity with age.</p><p>The earliest ultrastructural lesion is thinning of the GBM [<a href="#rid5">5,35</a>]. With time, there is development of longitudinal splitting of the lamina densa of the GBM, producing a laminated appearance that is diagnostic of Alport syndrome  (<a class="graphic graphic_picture graphicRef68942 graphicRef79434" href="/z/d/graphic/68942.html" rel="external">picture 1A-B</a>). In males with X-linked Alport syndrome, the proportion of GBM showing splitting increases from approximately 30 percent by age 10 to more than 90 percent by age 30 [<a href="#rid35">35</a>]. A similar progression likely occurs in patients with autosomal recessive Alport syndrome. Females with X-linked Alport syndrome, and males and females with autosomal dominant Alport syndrome, may have thin GBM or a mix of thin and lamellated GBM. (See  <a class="medical medical_review" href="/z/d/html/3038.html" rel="external">"Thin basement membrane nephropathy (benign familial hematuria)"</a>.)</p><p>Kidney biopsy of affected individuals at a young age may manifest only nonspecific light microscopic changes and no definitive electron microscopic findings. However, results of immunostaining for collagen IV alpha chains are frequently diagnostic even in the absence of specific ultrastructural changes. In some patients, less invasive skin biopsy with appropriate immunohistochemical analysis may be the preferred diagnostic study. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Diagnosis'</a> and <a class="local">'Skin'</a> below.)</p><p class="headingAnchor" id="H2052804607"><span class="h2">Skin</span><span class="headingEndMark"> — </span>Immunohistochemical studies with a monoclonal antibody directed against the alpha-5(IV) chain demonstrates complete absence of alpha-5(IV) chain within epidermal basement membranes in most males with X-linked Alport syndrome, while female carriers have discontinuous staining  (<a class="graphic graphic_picture graphicRef72404" href="/z/d/graphic/72404.html" rel="external">picture 2</a>) [<a href="#rid29">29</a>]. The latter observation is compatible with lyonization in female carriers, in whom it would be expected that one-half of their cells would express a normal alpha-5(IV) chain.</p><p>However, conventional immunofluorescence microscopy will detect alpha-5(IV) chain of the skin in approximately 20 percent of males with X-linked Alport syndrome and 30 to 40 percent of heterozygous females. All patients with autosomal recessive and autosomal dominant Alport syndrome have normal skin reactivity for alpha-5(IV)  (<a class="graphic graphic_picture graphicRef72404" href="/z/d/graphic/72404.html" rel="external">picture 2</a>). Thus, the presence of epidermal basement membrane staining for alpha-5(IV) does not exclude a diagnosis of X-linked or autosomal Alport syndrome. However, the absence of alpha-5(IV) chain in a skin biopsy is diagnostic of X-linked Alport syndrome.</p><p class="headingAnchor" id="H11"><span class="h2">Eye</span><span class="headingEndMark"> — </span>Anterior lenticonus, which is associated with thinning of the lens capsule, occurs in 20 to 30 percent of males with X-linked Alport syndrome as well as in patients with autosomal recessive Alport syndrome. If present, anterior lenticonus is pathognomonic for Alport syndrome. The lens capsule normally contains alpha-3, alpha-4, and alpha-5(IV) chains. In some patients with anterior lenticonus, these chains are absent from the lens capsule basement membrane [<a href="#rid36">36</a>]. Other ocular findings in patients with Alport syndrome include a distinctive dot-fleck retinopathy and, rarely, macular holes, likely related to the abnormal collagen IV composition of retinal basement membranes.</p><p class="headingAnchor" id="H12"><span class="h2">Cochlea</span><span class="headingEndMark"> — </span>Hearing loss in Alport syndrome likely reflects abnormal function of cochlear basement membranes due to the absence of the alpha-3-4-5 collagen IV network [<a href="#rid37">37</a>]. The precise mechanism for hearing loss in Alport syndrome remains under investigation.</p><p class="headingAnchor" id="H4203112289"><span class="h2">Aorta and intracranial arteries</span><span class="headingEndMark"> — </span>A growing number of case reports have described premature thoracoabdominal aortic aneurysm and dissection, as well as aneurysms of intracranial arteries, in patients, typically male, with X-linked Alport syndrome [<a href="#rid38">38,39</a>]. The collagen IV alpha-5-5-6 network is a normal component of arterial media, and its absence may predispose to aneurysm formation [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Arterial disease'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Leiomyomas</span><span class="headingEndMark"> — </span>Leiomyomas are benign tumors characterized by visceral smooth muscle overgrowth within the respiratory, gastrointestinal, and female reproductive tracts. Rarely, X-linked Alport syndrome is associated with leiomyomas. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Leiomyomatosis'</a>.)</p><p>Individuals who develop leiomyomas carry deletions that involve <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> and extend into the adjacent <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303631&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6Gb%2Bjs8Vg3v5ghAGYrmyIpe&amp;TOPIC_ID=6086" target="_blank"><i>COL4A6</i></a> gene [<a href="#rid41">41</a>]. Of note, defects in the alpha-6 chain gene alone do not appear to cause Alport syndrome [<a href="#rid5">5</a>]. The pathogenetic relationship between deletions of the 5' end of the <em>COL4A6</em> gene and the formation of leiomyomas is not understood. One hypothesis suggests that deletions that encompass both the <em>COL4A5</em> and <em>COL4A6</em> genes cause misregulation of neighboring genes, which contribute to smooth muscle overgrowth [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Alport syndrome (hereditary nephritis) is a progressive inherited form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the collagen IV protein family. It is a genetically heterogeneous disease with X-linked, autosomal recessive, and autosomal dominant variants. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The X-linked form accounts for the majority of affected patients. It arises from variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F303630&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6GuDNPxjxwS5lxr5ffuoR0b&amp;TOPIC_ID=6086" target="_blank"><i>COL4A5</i></a> gene on the X chromosome, which encodes alpha-5(IV) chains. (See <a class="local">'X-linked inheritance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The autosomal recessive form accounts for approximately 15 percent of patients with Alport syndrome. It arises from genetic defects in either the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a> genes, which encodes the alpha-3 and alpha-4(IV) chains, respectively. The clinical manifestations of affected patients regardless of sex are very similar to those of male patients with X-linked Alport syndrome. (See <a class="local">'Autosomal recessive inheritance'</a> above and  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autosomal dominant disease appears to account for 20 to 30 percent of patients with Alport syndrome, based on results of next-generation sequencing studies. It arises from heterozygous variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120070&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1RjfaNRysdmhVCcBiOUYk1V&amp;TOPIC_ID=6086" target="_blank"><i>COL4A3</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F120131&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1TpD72nzlbuUDIfJV2QRuro&amp;TOPIC_ID=6086" target="_blank"><i>COL4A4</i></a> genes. The clinical and pathologic features of this form of Alport syndrome are similar to those of X-linked disease, although deterioration of kidney function tends to occur more slowly and sensorineural hearing loss and ocular abnormalities are unusual. (See <a class="local">'Autosomal dominant inheritance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Pathogenic variants in genes that encode the alpha-3, alpha-4, and alpha-5(IV) chains cause disruption of the normal collagen network  (<a class="graphic graphic_figure graphicRef130689" href="/z/d/graphic/130689.html" rel="external">figure 1</a>) found in the basement membrane of the cochlea; eye; and the kidney's Bowman capsule, glomerulus, and distal and collecting tubules. These abnormalities impair the integrity of basement membranes in these sites, leading to the various clinical findings of Alport syndrome. (See  <a class="medical medical_review" href="/z/d/html/6093.html" rel="external">"Clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis)", section on 'Clinical manifestations and course'</a> and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunostaining</strong> – In patients with Alport syndrome, immunostaining of kidney tissue is usually diagnostic demonstrating absence of alpha-3, alpha-4, and alpha-5(IV) chains. In addition, immunostaining of skin tissue directed against the alpha-5(IV) chain demonstrates complete absence of alpha-5(IV) chain within epidermal basement membranes in most males with X-linked Alport syndrome. (See <a class="local">'Immunostaining'</a> above and <a class="local">'Skin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Histology</strong> – Histologic changes in the kidney increase in severity with age. The earliest finding is thinning of the glomerular basement membrane (GBM). With increasing age, longitudinal splitting of the lamina densa of the GBM produces a laminated appearance that is diagnostic of Alport syndrome and is present in 90 percent of male patients by 30 years of age  (<a class="graphic graphic_picture graphicRef68942 graphicRef79434" href="/z/d/graphic/68942.html" rel="external">picture 1A-B</a>). (See <a class="local">'Histologic changes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 2018; 93:1045.</a></li><li><a class="nounderline abstract_t">Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15:2514.</a></li><li><a class="nounderline abstract_t">Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 2014; 86:252.</a></li><li><a class="nounderline abstract_t">Morinière V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 2014; 25:2740.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Michael AF. Alport syndrome. Kidney Int 1996; 50:1445.</a></li><li><a class="nounderline abstract_t">Heiskari N, Zhang X, Zhou J, et al. Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 1996; 7:702.</a></li><li><a class="nounderline abstract_t">Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int 1993; 43:38.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.</a></li><li><a class="nounderline abstract_t">Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.</a></li><li><a class="nounderline abstract_t">Torra R, Tazón-Vega B, Ars E, Ballarín J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 2004; 19:2429.</a></li><li><a class="nounderline abstract_t">Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224.</a></li><li><a class="nounderline abstract_t">Antignac C, Knebelmann B, Drouot L, et al. Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression. J Clin Invest 1994; 93:1195.</a></li><li><a class="nounderline abstract_t">Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 2004; 15:1466.</a></li><li><a class="nounderline abstract_t">Dagher H, Buzza M, Colville D, et al. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 2001; 38:1217.</a></li><li><a class="nounderline abstract_t">Rheault MN, Kren SM, Hartich LA, et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010; 25:764.</a></li><li><a class="nounderline abstract_t">Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8:77.</a></li><li><a class="nounderline abstract_t">Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 2006; 21:665.</a></li><li><a class="nounderline abstract_t">van der Loop FT, Heidet L, Timmer ED, et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 2000; 58:1870.</a></li><li><a class="nounderline abstract_t">Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002; 61:1947.</a></li><li><a class="nounderline abstract_t">Pescucci C, Mari F, Longo I, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 2004; 65:1598.</a></li><li><a class="nounderline abstract_t">Furlano M, Martínez V, Pybus M, et al. Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study. Am J Kidney Dis 2021; 78:560.</a></li><li><a class="nounderline abstract_t">Gross O, Netzer KO, Lambrecht R, et al. Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrol Dial Transplant 2003; 18:1122.</a></li><li><a class="nounderline abstract_t">Mencarelli MA, Heidet L, Storey H, et al. Evidence of digenic inheritance in Alport syndrome. J Med Genet 2015; 52:163.</a></li><li><a class="nounderline abstract_t">Kashtan CE. Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 2004; 16:177.</a></li><li><a class="nounderline abstract_t">McCoy RC, Johnson HK, Stone WJ, Wilson CB. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 1982; 21:642.</a></li><li><a class="nounderline abstract_t">Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42:179.</a></li><li><a class="nounderline abstract_t">Kim Y, Kleppel MM, Butkowski R, et al. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol 1991; 138:413.</a></li><li><a class="nounderline abstract_t">Kobayashi T, Uchiyama M. Characterization of assembly of recombinant type IV collagen alpha3, alpha4, and alpha5 chains in transfected cell strains. Kidney Int 2003; 64:1986.</a></li><li><a class="nounderline abstract_t">Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.</a></li><li><a class="nounderline abstract_t">Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg 2005; 131:1007.</a></li><li><a class="nounderline abstract_t">Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99:2470.</a></li><li><a class="nounderline abstract_t">Nakanishi K, Yoskikawa N, Iijima K, Nakamura H. Expression of type IV collagen alpha 3 and alpha 4 chain mRNA in X-linked Alport syndrome. J Am Soc Nephrol 1996; 7:938.</a></li><li><a class="nounderline abstract_t">Su J, Liu ZH, Zeng CH, et al. Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy. Nephrol Dial Transplant 2006; 21:1838.</a></li><li><a class="nounderline abstract_t">Naito I, Kawai S, Nomura S, et al. Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network. Kidney Int 1996; 50:304.</a></li><li><a class="nounderline abstract_t">Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.</a></li><li><a class="nounderline abstract_t">Cheong HI, Kashtan CE, Kim Y, et al. Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome. Lab Invest 1994; 70:553.</a></li><li><a class="nounderline abstract_t">Merchant SN, Burgess BJ, Adams JC, et al. Temporal bone histopathology in alport syndrome. Laryngoscope 2004; 114:1609.</a></li><li><a class="nounderline abstract_t">Earl TJ, Khan L, Hagau D, Fernandez AB. The spectrum of aortic pathology in alport syndrome: a case report and review of the literature. Am J Kidney Dis 2012; 60:821.</a></li><li><a class="nounderline abstract_t">Bose S, Pathireddy S, Baradhi KM, Aeddula NR. Alport's syndrome and intracranial aneurysm: mere coincidence or undiscovered causal relationship. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Kashtan CE, Segal Y, Flinter F, et al. Aortic abnormalities in males with Alport syndrome. Nephrol Dial Transplant 2010; 25:3554.</a></li><li><a class="nounderline abstract_t">Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 1995; 48:1900.</a></li></ol></div><div id="topicVersionRevision">Topic 6086 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551517" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alport syndrome: a unified classification of genetic disorders of collagen IVα345: a position paper of the Alport Syndrome Classification Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033287" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854265" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Improving mutation screening in familial hematuric nephropathies through next generation sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914010" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738805" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433568" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular genetics of Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Alport syndrome and thin glomerular basement membrane disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815141" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Alport's syndrome, Goodpasture's syndrome, and type IV collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280517" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349482" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of mutations in the COL4A5 collagen gene in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8132760" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153557" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mouse model of X-linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728953" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854849" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7987396" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338941" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044206" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12028435" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086897" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33838161" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical and Genetic Features of Autosomal Dominant Alport Syndrome: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748344" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575550" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence of digenic inheritance in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021198" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7047864" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635348" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992766" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differential expression of basement membrane collagen chains in diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633121" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Characterization of assembly of recombinant type IV collagen alpha3, alpha4, and alpha5 chains in transfected cell strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178947" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301374" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Distribution of type IV collagen in the cochlea in Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153291" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793804" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Expression of type IV collagen alpha 3 and alpha 4 chain mRNA in X-linked Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16574687" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8807602" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398144" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176894" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15475791" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Temporal bone histopathology in alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22950974" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The spectrum of aortic pathology in alport syndrome: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30700471" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Alport's syndrome and intracranial aneurysm: mere coincidence or undiscovered causal relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494893" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aortic abnormalities in males with Alport syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587250" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
